

- 院経営本部 平成15年度 臨床研究報告書, 2004; 167-169
50. 金川寿賀代、河野誠司、熊谷俊一. ステロイド誘発性骨粗鬆症と感受性遺伝子. リウマチ科, 2004; 31(5): 509-516
 51. Kageyama G, Kawano S, Kanagawa S, Kondo S, Sugita M, Nakanishi T, Shimizu A, Kumagai S. Effect of mutated transporters associated with antigen processing 2 on characteristic major histocompatibility complex binding peptides, an analysis of Electrospray Ionization-Tandem Mass Spectrometry. Rapid Commun Mass SP, 2004; 18: 995-1000
 52. Kumagai S, Komada F, Kita T, Morinobu A, Ozaki S, Ishida H, Sano H, Matsubara T, Okumura K. N-acetyltransferase 2 genotype-related efficacy of sulfasalazine in patients with rheumatoid arthritis. Pharm Res, 2004; 21(2): 324-329
 53. Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiwara H, Hirohata S, Makino H, Hashimoto H. Vertebral Fracture and Bone Mineral Density in Women Receiving High Dose Glucocorticoids for Treatment of Autoimmune Diseases. J Rheumatol, 2005; 32: in press
 54. 佐田憲映、山崎康司、槇野博史. ループス腎炎の病態と治療 解説 特集リウマチ科, 2004; 31: 227-233
 55. 佐田憲映、山崎康司、槇野博史. 腎血管炎をきたす疾患. リウマチ科, 2004; 31: 434-439
 56. 佐田憲映、山崎康司、槇野博史. 改訂されたループス腎炎 WHO 分類 解説. リウマチ科, 2004; 31: 612-619
 57. 佐田憲映、山崎康司、槇野博史. 推薦処方とその解説 ループス腎炎 解説 特集今月の治療, 2004; 12: 311-313
 58. Kikuchi H, Isshi K, Hirohata S. Inhibitory effects of bucillamine on the expression of vascular cell adhesion molecule-1 in human umbilical vein endothelial cells. Int Immunopharm, 2004; 4: 119-126
 59. Hirohata S, Yanagida T, et al. Enhanced generation of endothelial cells from CD34+ cells of the bone marrow in rheumatoid arthritis: possible role in synovial neovascularization. Arthritis Rheum, 2004; 50: 3888-3896
 60. Iwaki-Egawa S, Matsuno H, Yudoh K, Nakazawa F, Miyazaki K, Ochiai A, Hirohata S, Shimizu M, Watanabe Y. High diagnostic value of anticalpastatin autoantibodies in rheumatoid arthritis detected by ELISA using human erythrocyte calpastatin as antigen. J Rheumatol, 2004; 31: 17-22
 61. 広畑俊成. 特集 リウマチ性疾患治療の最前線 - 診断のポイントとベストの治療ガイドライン<難治性病態の治療戦略> 腸管 Behcet 病. 内科, 2004; 93: 309-311
 62. 大島信治、広畑俊成. 特集 膠原病とその類縁疾患と肺成人発症 Still 病と肺病変. 呼吸器科, 2004; 5: 242-246
 63. 広畑俊成. 特集 II 自己抗体 -最新の進歩抗リボソーム抗体と全身性エリテマトーデス. 炎症と免疫, 2004; 12: 293-299
 64. 広畑俊成. 関節リウマチ -基礎と臨床の最前線 病因と病態関節リウマチにおける B

- 細胞の関与 - 抗原特異的B細胞活性化. 医学のあゆみ, 2004; 209: 796-800
65. 広畑俊成、菊地弘敏. 特集：血管炎をきたす疾患の鑑別診断と治療中枢神経系に血管炎をきたす疾患. リウマチ科, 2004; 13: 447-451
 66. 広畑俊成. 特集：膠原病の難治性病態 中枢神経病変. 日臨免誌, 2004; 27: 109-117
 67. 鏑木淳一他. SLE、SLE 疑診例におけるループスアンチコアグラント測定の臨床的意義. 日本医事新報, 2004; 4208: 25-28
 68. 鏑木淳一他. 抗リン脂質抗体症候群の診断における抗ホスファチジルセリン・プロトロンビン複合体抗体の臨床的意義-多施設間成績-. 臨床血液, 2005; 46: 19-21
 69. Kondo H, Abe T, Hashimoto H, Uchida S, Irimajiri S, Hara M, Sugawara S. Efficacy and safety of Tacrolimus (FK506) in treatment of rheumatoid arthritis: A randomized, double blind, placebo controlled dose-finding study. J Rheumatol, 2004; 31(2): 243-251
 70. Okamoto H, Soejima M, Takeuchi M, Tateishi M, Terai C, Hara M, Saito T, Kamatani N. Dermatomyositis associated with autoimmune idiopathic thrombocytopenia and anti-Ku antibody. Mod Rheumatol, 2004; 14(2): 187-190
 71. Kobashigawa T, Okamoto H, Kato J, Shindo H, Imamura T, Iizuka B, Tanaka M, Uesato M, Ohta S, Terai C, Hara M, Kamatani N. Ulcerative colitis followed by the development of Behcet's disease. Internal Medicine, 2004; 43(3): 243-247
 72. Hara M, Abe T, Sugawara S, Mizushima Y, Hoshi K, Irimajiri S, Hashimoto H, Yoshino S, Matsui N, Nobunaga M. A phase III, double blind, comparative study to evaluate the efficacy and safety of T-614, a newly developed DMARD. Ann Rheum Dis, 2004; 63: 91
 73. Kajiyama H, Terai C, A. de Bellis, A. Bizzarro, A. Bellastella, Ohta S, Okamoto H, Uesato M, Hara M, Kamatani N. Vasopressin cell antibodies and central diabetes insipidus in a patient with systemic lupus erythematosus and dermatomyositis. J Rheumatol, 2004; 31(6): 1218-1221
 74. Harigai M, Hara M, Kawamoto M, Kawaguchi Y, Sugiura T, Tanaka M, Nakagawa M, Ichida H, Takagi K, S.H. Osako, Shimada K, Kamatani N. Amplification of the synovial inflammatory response through activation of mitogen-activated protein kinases and nuclear factor kB using ligation of CD40 on CD14+ synovial cells from patients with rheumatoid arthritis. Arthritis Rheum, 2004; 50(7): 2167-2177
 75. Nishimagi E, Hirata S, Kawaguchi Y, Okamoto H, Hara M, Kamatani N. Myocardial dysfunction in a patient with adult-onset Still's disease(AOSD). Clin Exp Rheumatol, 2004; 22: 506-507
 76. Nishimagi E, Kawaguchi Y, Tanaka E, Hara M, Kamatani N. Classification of systemic sclerosis in the japanese population based on rapid progression of skin thickening. Mod Rheumatol, 2004; 14: 216-221
 77. 原まさ子、田中栄一. 膠原病に合併した合併肺高血圧症の治療. 免疫疾患の合併症とその治療法に関する研究 平成15年度総括研究報告書, 2004; 36-37
 78. 原まさ子. 多発性筋炎・皮膚筋炎. 内科, 2004; 93(2): 259-263

79. 原まさ子. 関節リウマチにおけるマクロファージ系滑膜細胞-T細胞間相互作用とその新規治療への応用のに関する研究 慢性関節リウマチの難治性病態に対する新規治療法の開発研究に関する研究. 平成15年度総括・分担研究報告書, 2004; 23-25
80. 原まさ子. 膠原病に伴う2次性肺高血圧症患者における疾患感受性遺伝子の検討 混合性結合組織病の病態、治療と関連する遺伝的因子、自己抗体の研究. 平成15年度総括・分担研究報告書, 2004; 56-59
81. Miyachi K, Hirano Y, Horigome T, Mimori T, Miyakawa H, Onozuka Y, Shibata M, Hirakata M, Suwa A, Hosaka H, Matsushima S, Komatsu T, Matsushima H, Raleigh Hankins, Marvin Fritzler. Autoantibodies from primary biliary cirrhosis patients with anti-p95c antibodies bind to recombinant p97/VCP and inhibit in vitro nuclear envelope assembly. *Clin Exp Immunol*, 2004; 136: 568-573
82. Kaneko Y, Hirakata M, Suwa A, Sato S, Ikeda Y, Mimori T. A case of systemic lupus erythematosus associated with lupus enteritis and peritonitis. *Clin Rheumatol*, 2004; 23: 351-354
83. Hirakata M, Suwa A, Kuwana M, Sato S, Mimori T, John A. Hardin. Autoantibodies to the Ku protein are associated with the DPB1 gene. *Arthritis Rheum*, 2005; 52(2): 668-669
84. 加藤雅史、佐藤慎二、鈴木美佐子、岡 浩子、金子祐子、安岡秀剛、野島崇樹、諏訪 昭、平形道人、池田康夫. 血球貪食症候群 (HPS) に体してシクロホスファミド間歇静注療法が奏功した混合性結合組織病 (MCTD) の一例. *日臨免誌*, 2004; 27(5): 345-349
85. 藤井隆夫、佐藤慎二、諏訪 昭、野島崇樹、三森経世、平形道人. メトトレキサート抵抗性の関節リウマチ患者に対するミゾリビン追加併用療法の検討. *Pharma Medica*, 2004; 22(6): 73-79
86. 諏訪 昭、金子祐子、野島崇樹. リウマチ性疾患に伴う血液異常. *Medicina*, 2004; 40(5): 838-840
87. 諏訪 昭. 自己抗体陽性 診断と治療, 2004; 92(2): 241-246
88. Hagiyaama H, Kubota T, Komano Y, Kurosaki M, Watanabe M, Miyasaka N. Fulminant hepatitis in an asymptomatic chronic carrier of hepatitis B virus mutant after withdrawal of low-dose methotrexate therapy for rheumatoid arthritis. *Clin Exp Rheumatol*, 2004; 22: 375-376
89. Nanki T, Urasaki Y, Imai T, Nishimura M, Muramoto K, Kubota T, Miyasaka N. Inhibition of fractalkine ameliorates murine collagen-induced arthritis. *J Immunol*, 2004; 171: 4913-4919
90. Komano Y, Kubota T, Wakabayashi S, Ochi S, Nonomura Y, Hagiyaama H, Nanki T, Kohsaka H, Miyasaka N. A case of paraneoplastic syndrome mimicking adult-onset Still's disease. *Mod Rheumatol*, 2004; 14: 410-413
91. Ogawa J, Harigai M, Nagasaka K, Nakamura T, Miyasaka N. Prediction of and prophylaxis against *Pneumocystis pneumonia* in patients with connective tissue diseases undergoing medium- or high-dose corticosteroids therapy. *Mod Rheumatol*, in press
92. Li N, Nakamura K, Jiang Y, Tsurui H, Matsuoka S, Abe M, Ohtsuji M, Nishimura H,

- Kato K, Kawai T, Atsumi T, Koike T, Shirai T, Ueno H, Hirose S. Gain-of-function polymorphism in mouse and human Ltk: implications for the pathogenesis of systemic lupus erythematosus. *Hum Mol Genet*, 2004; 13: 171-179
93. Das H, Atsumi T, Fukushima Y, Shibuya H, Ito K, Amasaki Y, Ichikawa K, Yamada Y, Koike T. Specificity of anti-agalactosyl IgG antibodies for diagnosing rheumatoid arthritis. *Clin Rheumatol*, 2004; 23: 218-22
 94. Yasuda S, Atsumi T, Ieko M, Matsuura E, Kobayashi K, Inagaki J, Kato H, Tanaka H, Yamakado M, Akino M, Saitou H, Amasaki Y, Jodo S, Amengual O, Koike T. Nicked beta2-glycoprotein I: A marker of cerebral infarct and a novel role in the negative feedback pathway of extrinsic fibrinolysis. *Blood*, 2004; 103: 3766-3782
 95. Sanchez ML, Katsumata K, Atsumi T, Romero FI, Bertolaccini ML, Funke A, Amengual O, Kondeates E, Vaughan RWW, Cox A, Khamashta MA, Hughes RV Association of HLA-DM polymorphism with the production of antiOospholipid antibodies. *Ann Rheum Dis*, 2004; 63: 1645-1648
 96. Amengual O, Atsumi T, Koike T. Antiprothombin antibodies and the diagnosis of antiphospholipid syndrome. *Clin Immunol*, 2004; 112: 144-149
 97. Bohgaki M, Atsumi T, Yamashita Y, Yasuda S, Sakai Y, Furusaki A, Bohgaki T, Amengual O, Amasaki Y, Koike T. The p38 mitogen-activated protein kinase (MAPK) pathway mediates induction of the tissue factor gene in monocytes stimulated with human monoclonal anti-beta2 Glycoprotein I antibodies. *Int Immunol*, 2004; 16: 1633-1641
 98. Atsumi T, Amengual O, Yasuda S, Koike T. Antiprothrombin Antibodies : Are they worth assaying ? *Thromb Res*, 2004; 114: 533-538
 99. Yasuda S, Atsumi T, Ieko M, Koike T β 2-glycoprotein I, anti- β 2-glycoprotein I and Fibrinolysis. *Thromb Res*, 2004; 114: 461-465
 100. Sugiura-Ogasawara M, Atsumi T, Ozaki Y, Koike T, Suzumori K. Phosphatidylserine-dependent antiprothrombin antibodies are not useful markers for high-risk women with recurrent miscarriages. *Fertil Steril*, 2004; 82: 1440-1442
 101. Hashimoto T, Jodo S, Furusaki A, Kon Y, Amasaki Y, Atsumi T, Komatsu H, Shimokawa J, Yonezawa K, Koike T. A woman with infectious endocarditis caused by *Abiotrophia defectiva*. *Intern Med*, 2004; 43: 1000-1004
 102. Yasuda S, Atsumi T, Matsuura E, Kaihara K, Yamamoto D, Ichikawa K, Koike T. Significance of valine/leucine247 polymorphism of beta2-glycoprotein I in antiphospholipid syndrome: increased reactivity of anti-beta2-glycoprotein I autoantibodies to the valine247 beta2-glycoprotein I variant. *Arthritis Rheum*, 2005; 52: 212-218
 103. Bertolaccini ML, Atsumi T, Koike T, Hughes GRV, Khamashta MA. Antiprothrombin antibodies detected in two different assay systems: prevalence and clinical significance in systemic lupus erythematosus. *Thromb Haemost*, 2005; 93: 289-297
 104. Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiyaama H, Hirohata S, Makino H, Hashimoto H. Analysis of vertebral

- fracture and bone mineral density in women receiving high-dose glucocorticoids for treatment of autoimmune diseases. *J Rheumatol*, 2005 in press
105. Atsumi T, Furukawa S, Koike T. Antiphospholipid antibody associated thrombocytopenia and the paradoxical risk of thrombosis. *Lupus*, in press
 106. Nakayamada S, Okada Y, Saito K, Tanaka Y. Etidronate prevents high-dose glucocorticoid-induced bone loss in premenopausal individuals with systemic autoimmune diseases. *J Rheumatol*, 2004; 31: 163-166
 107. Tanikawa T, Okada Y, Azuma T, Fukushima A, Kawahara C, Tanaka Y. Adult-onset idiopathic progressive acro-ostolysis with proximal symphalangism. *J Bone Miner Res*, 2004; 1: 165-167
 108. Kawahara C, Okada Y, Tanikawa T, Misawa H, Fukushima A, Tanaka Y. Severe hypercalcemia and hypernatremia associated with calcipotriol for treatment of psoriasis. *J Bone Miner Metab*, 2004; 22: 159-162
 109. Okada Y, Tanaka Y. Immune signalings in the context of secondary osteoporosis. *Histol Histopathol*, 2004; 19: 863-866
 110. Okada Y, Tsukada J, Nakano K, Tonai S, Mine S, Tanaka Y. Macrophage inflammatory protein-1 induces hypercalcemia in adult T-cell leukemia. *J Bone Miner Res*, 2004; 19: 1105-1111
 111. Nakano K, Okada Y, K Saito, Y Tanaka. Induction of RANKL expression and osteoclast maturation by the binding of fibroblast growth factor 2 to heparan sulfate proteoglycan on rheumatoid synovial fibroblasts. *Arthritis Rheum*, 2004; 50: 2450-2458
 112. Tanaka Y, Okada Y. Acro-osteolysis and Symphalangism Mutations. *J Bone Miner Res*, 2005; 20: 160
 113. Tanaka Y, Nakayamada S, Okada Y. Osteoblasts and osteoclasts in bone remodeling and inflammation. *Current drug targets*, in press
 114. Kumagai S, Kawano S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburaki J, Kameda H, Suwa A, Hagiwara H, Hirohata S, Makino H, Hashimoto H. Frequent vertebral fractures while BMD is maintained in pre-menopausal patients receiving high-dose glucocorticoids for treatment of autoimmune diseases. *J Rheumatol*, 2005 in press
 115. 岡田洋右, 田中良哉. 膠原病患者におけるステロイド性骨粗鬆症の一次予防の検討. *Osteoporosis Japan*, 2004; 12: 321-323
 116. 田中良哉, 岡田洋右. 癌と骨病変 ―癌と骨組織との相互作用―ランゲルハンス細胞組織球症. *Molecular Medicine*, 2004; 41: 1382-1386
 117. 田中良哉, 中山田真吾, 岡田洋右. ビスホスフォネート製剤によるステロイド性骨粗鬆症の一次予防. *DENTAL DIAMOND*, in press
 118. 岡田洋右, 田中良哉. ステロイド性骨粗鬆症における一次予防. *Osteoporosis Japan*, in press
 119. Kameda H, Amano K, Sekiguchi N, Takei H, Ogawa H, Nagasawa H, Takeuchi T. Factors predicting the response to low-dose methotrexate therapy in patients with

- rheumatoid arthritis: a better response in male patients. *Mod Rheumatol*, 2004; 14: 442-446
120. Kameda H, Ishigami H, Abe T, Takeuchi T. Expression of adapter proteins in rheumatoid synovial fibroblast-like cells and their involvements in signaling from growth factor receptors. *Ann Rheum Dis*, 2004; 50(9): S156
 121. Mori T, Kameda H, Ogawa H, Iizuka A, Sekiguchi N, Takei H, Nagasawa H, Tokuhira M, Tanaka T, Saito Y, Amano K, Abe T, Takeuchi T. Incidence of cytomegalovirus reactivation in patients with inflammatory connective tissue diseases who are under immunosuppressive therapy. *J Rheumatol*, 2004; 31: 1349-1351
 122. Kameda H, Ishigami H, Abe T, Takeuchi T. Blockade of signaling from growth factor receptors by STI571 inhibits both anchorage-dependent and independent growth of rheumatoid synovial fibroblast-like cells. *Arthritis Rheum*, 2004; 63(Suppl. 1): 150
 123. 亀田秀人. CTLA4-IgによるSLEの治療. *リウマチ科*, 2004; 31(1): 566-572
 124. 亀田秀人. シクロホスファミドー古くて新しい免疫抑制薬. *医学のあゆみ*, 2004; 210(13): 1040-1043
 125. 鈴木勝也, 亀田秀人, 竹内 勤. PD-1と自己免疫. *炎症と免疫*, 2004; 12(6): 106-110
 126. 鐙木淳一, 桑名正隆, 亀田秀人, 竹内勤, 岡田純, 片山雅夫, 吉田俊治, 池田康夫. SLE・SLE疑診例におけるループスアンチコアグラント測定の臨床的意義. *日本醫事新報*, 2004; 4208: 25-28
 127. 亀田秀人, 竹内 勤. 膠原病肺病変に対するシクロスポリン療法. *呼吸*, 2004; 23(1): 47-51
 128. 亀田秀人, 長澤逸人, 竹内 勤. 膠原病関連間質性肺炎の治療. *分子呼吸器病*, 2004; 8(2): 132-138
 129. Kempe K, Tsuda H, Yang KS, Yamaji K, Kanai Y, Hashimoto H: Filtration leukocytapheresis therapy in the treatment of rheumatoid arthritis patients resistant to or failed with methotrexate. *Ther Apher Dial*, 2004; 8(3): 197-205
 130. Kumagai S, Kawana S, Atsumi T, Inokuma S, Okada Y, Kanai Y, Kaburagi J, Kameda H, Suwa A, Hagiyaama H, Hirohata S, Makino H, Hashimoto H. Vertebral fracture and bone mineral density in women receiving high dose glucocorticoids for treatment of autoimmune disease. *J Rheumatol*, 2005; 32 in press
 131. 橋本博史, 金井美紀. 気をつけたいステロイド剤の副作用. *臨床と研究*, 2004; 81: 62-66
 132. 渡辺 仁, 金井美紀, 津田裕士, 橋本博史. 関節リウマチ患者における長期血漿交換療法のQOLへの影響. *日アフェレンス会誌*, 2005; 24: 75-83